Acumen Pharmaceuticals (ABOS) Times Interest Earned (2020 - 2026)
Acumen Pharmaceuticals (ABOS) posted Times Interest Earned of -$19.78 for Q1 2026, up 42.53% sequentially from -$34.42 in Q4 2025, and up 33.36% YoY from -$14.84 in Q1 2025.
Acumen Pharmaceuticals (ABOS) Times Interest Earned (2020 - 2026) Analysis & Trends
Acumen Pharmaceuticals has reported Times Interest Earned for 7 years, with the latest figure at -$19.78 in Q1 2026.
- Quarterly Times Interest Earned rose 33.36% year-over-year to -$19.78 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$29.27 (down 12.69% YoY) and the FY2025 annual result came in at -$1.45, up 28.33% from the prior year.
- Times Interest Earned grew to -$19.78 in Q1 2026 per ABOS's latest filing, from -$34.42 in the prior quarter.
- Over five years, Times Interest Earned peaked at $124.98 in Q4 2022 and troughed at -$336.95 in Q2 2023.
- A 5-year average of -$71.06 and a median of -$27.26 in 2025 frame the typical range for Times Interest Earned.
- The sharpest annual moves came in 2022 and 2023: Times Interest Earned surged 99.83% in 2022, then sank 40356.01% in 2023.
- Over 5 years, Times Interest Earned stood at $124.98 in 2022, then sank by 187.52% to -$109.38 in 2023, then jumped by 80.11% to -$21.76 in 2024, then tumbled by 58.23% to -$34.42 in 2025, then jumped by 42.53% to -$19.78 in 2026.
- According to Business Quant data, Times Interest Earned over the past three periods registered -$19.78, -$34.42, and -$24.82 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 2.82 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 76.86 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.08 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.42 |
| 10 | Acumen Pharmaceuticals | 226.87 Mn | 226.87 Mn | - | -29.76 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -29.76 |
| Mar 31, 2026 | -19.78 |
| Dec 31, 2025 | -34.42 |
| Sep 30, 2025 | -24.82 |
| Jun 30, 2025 | -39.91 |
| Mar 31, 2025 | -29.69 |
| Dec 31, 2024 | -21.76 |
| Sep 30, 2024 | -31.42 |
| Jun 30, 2024 | -24.28 |
| Mar 31, 2024 | -17.77 |
| Dec 31, 2023 | -109.38 |
| Jun 30, 2023 | -336.95 |
| Mar 31, 2023 | -328.38 |
| Dec 31, 2022 | 124.98 |
| Sep 30, 2022 | -0.29 |
| Jun 30, 2022 | -0.83 |
| Mar 31, 2022 | -242.26 |
| Dec 31, 2021 | 365.87 |
| Sep 30, 2021 | -171.09 |
| Jun 30, 2021 | -0.07 |